ReproNovo ApS: Financial statements 2025
CVR: 44291908
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ReproNovo ApS (CVR 44291908) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 18,904,345 and a net result of DKK 1,523,599. Equity in the 2025 report amounted to DKK 2,778,020. The solvency ratio was 16%. The company had 10 employees in the financial year.
- Gross Profit
- DKK 18,904,345
- Profit/Loss
- DKK 1,523,599
- Equity
- DKK 2,778,020
- Total Assets
- DKK 17,314,709
- Employees
- 10
Official annual report
How creditworthy is ReproNovo ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
ReproNovo ApS has published its interim report for the period September 7, 2023 to December 31, 2024.
As of June 24, 2025, Ecovis Danmark statsautoriseret revisionsinteressentskab has been appointed auditor of ReproNovo ApS.
About ReproNovo ApS
ReproNovo ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Joan Carles Arce Saez. The board consists of BingMei Hao (chair), Jean Marie Duvall and Joan Carles Arce Saez. The company is owned by ReproNovo SA. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK 18,904,345 and a net result of DKK 1,523,599. Equity in the 2025 report amounted to DKK 2,778,020.